Genmab A/S (NASDAQ:GMAB) Earns Outperform Rating from Analysts at Royal Bank of Canada

Royal Bank of Canada started coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research note published on Monday, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $23.00 target price on the stock.

Separately, Morgan Stanley assumed coverage on shares of Genmab A/S in a research note on Monday. They issued an overweight rating on the stock.

Shares of NASDAQ GMAB opened at $19.89 on Monday. Genmab A/S has a 52 week low of $12.10 and a 52 week high of $21.45.



An institutional investor recently bought a new position in Genmab A/S stock. Parametric Portfolio Associates LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMAB) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 375,476 shares of the company’s stock, valued at approximately $6,937,000. Parametric Portfolio Associates LLC owned about 0.29% of Genmab A/S at the end of the most recent reporting period. 0.80% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Further Reading: How Does the Quiet Period Work?

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.